Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Name of medicine

ZEPOSIA

Study drug International non-proprietary name (INN) or common name

OZANIMOD HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) code

(L04AA38) ozanimod
ozanimod

Medical condition to be studied

Multiple sclerosis
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

9000
Study design details

Main study objective

To assess the rate of adverse events in those taking Zeposia compared to two comparator groups.

Outcomes

The primary endpoints of interest are major acute cardiovascular events (MACE) (composite and the individual components of MACE), serious opportunistic infections, serious acute liver injury, macular edema, and malignancy. The secondary outcomes are PRES, PML and symptomatic bradycardia.

Data analysis plan

Incidence rates of MACE, SOI, SALI, macular edema, and malignancy for eligible new users of ozanimod and comparator agents will be estimated and compared at the treatment episode level. Incidence rates will be reported as point estimates (in cases per 1,000 person-years) and 95% CI. Incidence rates and hazard ratios of the “other DMT” cohort will also be reported stratified by route of administration (i.e.: oral, intravenous infusion and self-injectables).